Çakir T.Ara C.Soyer H.V.Koc S.2024-08-042024-08-0420151757-790Xhttps://doi.org/10.1136/bcr-2015-209448https://hdl.handle.net/11616/91802Progressive liver failure is rarely seen in tuberculosis chemoprophylaxis with isoniazid. We present a case of a 32-year-old woman admitted to our clinic reporting abdominal pain, nausea and vomiting for 2 days. The initial diagnosis was fulminant toxic hepatitis due to isoniazid chemoprophylaxis, which was treated successfully with living donor transplantation. Tuberculosis continues to be a significant public health problem. Isoniazid-related hepatotoxicity is extremely rare in adults. The only treatment in cases of fulminant liver failure is orthotopic liver transplantation from a deceased or living donor. If a deceased donor is not available or the patient refuses this treatment, living donor transplantation is the only choice. Although rare, isoniazid used as protective therapy for pulmonary tuberculosis can lead to fulminant liver failure. When cadaveric liver transplantation is not available, living donor liver transplantation is vital. © 2015 CrossMark.eninfo:eu-repo/semantics/openAccessalanine aminotransferasealbuminammoniaaspartate aminotransferasebilirubinC reactive proteincreatininegamma glutamyltransferasehemoglobinisoniazidmethylprednisolonenitrogentacrolimusureaisoniazidtuberculostatic agentabdominal painadultarterial gasArticlebrain diseasecase reportchemoprophylaxisconsciousness disorderdeliriumdisease associationdisease durationdisease exacerbationdrug blood leveldrug withdrawalfemalefulminant hepatic failurehumanhuman tissueimmunosuppressive treatmentinternational normalized ratiojaundicelength of stayleukocyte countliver graft rejectionliver toxicityliver transplantationliving donormultidetector computed tomographynausea and vomitingpartial thromboplastin timepriority journalprothrombin timesomnolencethrombocyte counttuberculosisurea nitrogen blood levelchemically inducedLiver Failure, AcutetuberculosisAdultAntitubercular AgentsFemaleHumansIsoniazidLiver Failure, AcuteLiver TransplantationLiving DonorsTuberculosisArticle20152610617510.1136/bcr-2015-2094482-s2.0-84938889344Q3